Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on May 15, 2020. The filing discloses two material events: the incurrence of a new direct financial obligation and the appointment of a new Chief Financial Officer.
Key Financial Metrics and Obligations
- New Debt: Borrowed an additional $1.0 million under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due on March 30, 2023.
- Executive Compensation: New CFO Andrea Park received a base salary of $265,000, a target bonus of 40% of base salary, and options to purchase 300,000 shares at $0.738 per share.
- Consulting Fees: Former CFO Russell Skibsted will be compensated at $300 per hour or $1,800 per day for consulting services.
Material Changes and Events
Debt Facility: The company utilized available credit under an existing facility dated March 30, 2020. The agreement includes extensive "Events of Default" clauses, including failure to pay, insolvency, material adverse changes in financial condition, or loss of collateral, which could accelerate repayment.
Leadership Transition: Andrea Park was appointed Chief Financial Officer, replacing Russell Skibsted. Ms. Park previously served as the company's Vice President of Finance and Controller since October 2019.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ materially due to risk factors detailed in periodic SEC reports.
Default Risks: The new loan agreement allows the lender to declare the debt immediately due and payable if an Event of Default occurs and remains uncured for 10 business days. Specific triggers include cross-defaults on other indebtedness exceeding $100,000 or failure to pay debts exceeding $25,000 when due.
Equity Vesting: The stock options granted to the new CFO vest 25% after one year and the remainder over 36 months, contingent on continuous service. Early termination results in expiration of unvested options within three months.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement with Juvenescence Limited.
- Confirm the status of the company's liquidity and ability to meet the March 30, 2023 repayment date.
- Review the Security Agreement referenced in the loan to understand the specific assets pledged as collateral.
- Monitor the vesting schedule and potential dilution impact of the 300,000 options granted to the new CFO.
- Check for any subsequent filings regarding the departure of Russell Skibsted or changes in the consulting arrangement.